logo

For the Inventor, By the Inventor

Wayland, MA, United States of America

Ray Camphausen

LinkedIn
USPTO Granted Patents = 45 

 

Average Co-Inventor Count = 5.4

ph-index = 16

Forward Citations = 679(Granted Patents)


Company Filing History:

goldMedal44 out of 3,684 
 
Bristol-myers Squibb Compnay
 patents
silverMedal1 out of 41 
 
Bristol Meyers Squibb Company
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
FGF-21 Polypeptides
Fibronectin Binding Domains
Targeted Therapeutics
Engineered Proteins
Cancer Treatment
PCSK9 Binding
Serum Albumin Binding
Bispecific Molecules
Multivalent Scaffold Proteins
Tyrosine Kinase Receptors
Fc Fusion Proteins
Improved Stability
45 patents (USPTO):Explore Patents
1. 12247058 - Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof (2025-03-11),
2. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9 (2024-01-02),
3. 11408093 - Fibronectin binding domains with reduced immunogenicity (2022-08-09),
4. 11279751 - Fibronectin binding domains with reduced immunogenicity (2022-03-22),
5. 11248031 - Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides (2022-02-15),
6. 11203630 - Serum albumin-binding fibronectin type III domains (2021-12-21),
7. 11161893 - Fibronectin based scaffold proteins having improved stability (2021-11-02),
8. 11149077 - Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR (2021-10-19),
9. 10954286 - Bispecific EGFR/IGFIR binding molecules (2021-03-23),
10. 10947297 - Fibronectin based scaffold domain proteins that bind PCSK9 (2021-03-16),
11. 10934572 - Serum albumin binding molecules (2021-03-02),
12. 10781247 - Targeted therapeutics based on engineered proteins that bind EGFR (2020-09-22),
13. 10774130 - Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins (2020-09-15),
14. 10604556 - Fibronectin binding domains with reduced immunogenicity (2020-03-31),
15. 10464995 - Fibronectin binding domains with reduced immunogenicity (2019-11-05),

Title: Ray Camphausen: Pioneering Innovator in Medical Technology

Introduction: Ray Camphausen, hailing from Wayland, MA, is a visionary inventor whose unyielding dedication to innovation has significantly impacted the realm of modern technology. With a remarkable portfolio of 44 patents, his groundbreaking contributions continue to inspire aspiring inventors globally.

Latest Patents: Among his latest patents is the development of Fibronectin based scaffold domain proteins that bind PCSK9. These novel proteins have revolutionized therapeutic applications for treating atherosclerosis, hypercholesterolemia, and other cholesterol-related diseases, showcasing Ray's ingenuity in the medical field. Additionally, his work on Fibronectin binding domains with reduced immunogenicity demonstrates his commitment to advancing biotechnology with cutting-edge designs.

Career Highlights: Ray's illustrious career includes tenure at renowned companies such as Bristol-Myers Squibb. His expertise and innovative prowess have led to the creation of groundbreaking technologies, positioning him as a trailblazer in the industry.

Collaborations: Throughout his journey, Ray has collaborated with esteemed professionals in the field, including Dasa Lipovsek and Jonathan Harry Davis. Together, they have spearheaded innovative projects that have pushed the boundaries of scientific discovery.

Conclusion: Ray Camphausen's exceptional contributions underscore his status as a pioneer in medical technology, reshaping the landscape of innovation. His legacy serves as a beacon of inspiration for future generations of inventors, solidifying his place in the pantheon of great inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…